NBY

NOVABAY PHARMA
AMEX

实时行情|Nasdaq Last Sale

0.7310
-0.1290
-15.00%
盘后: 0.7600 +0.029 +3.97% 16:11 04/02 EDT
开盘
0.8200
昨收
0.8600
最高
0.9000
最低
0.7200
成交量
586.99万
成交额
--
52周最高
4.040
52周最低
0.2290
市值
2,047.57万
市盈率(TTM)
-1.4096
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NBY价格均价为1.500,最高价位1.500,最低价为1.500。

EPS

NBY 新闻

更多
  • NovaBay EPS misses by $0.06, misses on revenue
  • seekingalpha · 6天前
  • NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 6天前
  • NovaBay Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results
  • Business Wire · 6天前
  • NovaBay Pharmaceuticals, Inc. to Host Earnings Call
  • ACCESSWIRE · 03/26 19:30

所属板块

生物技术和医学研究
+2.93%
制药与医学研究
+2.57%

热门股票

代码
价格
涨跌幅

NBY 简况

NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
展开

微牛提供NovaBay Pharmaceuticals, Inc.(AMEX-NBY)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NBY股票新闻,以帮助您做出投资决策。